Compare with Torrent Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALKEM LABORATORIES vs TORRENT PHARMA - Comparison Results

TORRENT PHARMA 
   Change

Torrent Pharmaceuticals Ltd. is the flagship company of the Torrent Group set up in 1959. Based in Ahmedabad, it was promoted by Mr U.N. Mehta initially as Trinity Laboratories Ltd. and was later renamed to its current name. The company derives its r... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALKEM LABORATORIES TORRENT PHARMA ALKEM LABORATORIES/
TORRENT PHARMA
 
P/E (TTM) x 22.7 34.5 65.7% View Chart
P/BV x 5.5 8.7 62.6% View Chart
Dividend Yield % 0.9 0.7 127.3%  

Financials

 ALKEM LABORATORIES   TORRENT PHARMA
EQUITY SHARE DATA
    ALKEM LABORATORIES
Mar-20
TORRENT PHARMA
Mar-19
ALKEM LABORATORIES/
TORRENT PHARMA
5-Yr Chart
Click to enlarge
High Rs2,7201,964 138.5%   
Low Rs1,6601,245 133.4%   
Sales per share (Unadj.) Rs697.9453.4 153.9%  
Earnings per share (Unadj.) Rs96.125.8 372.8%  
Cash flow per share (Unadj.) Rs117.362.3 188.3%  
Dividends per share (Unadj.) Rs25.0017.00 147.1%  
Dividend yield (eoy) %1.11.1 107.7%  
Book value per share (Unadj.) Rs515.2279.2 184.6%  
Shares outstanding (eoy) m119.57169.22 70.7%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.13.5 88.7%   
Avg P/E ratio x22.862.2 36.6%  
P/CF ratio (eoy) x18.725.8 72.5%  
Price / Book Value ratio x4.35.7 74.0%  
Dividend payout %26.065.9 39.4%   
Avg Mkt Cap Rs m261,879271,513 96.5%   
No. of employees `00014.313.6 105.4%   
Total wages/salary Rs m15,05514,038 107.2%   
Avg. sales/employee Rs Th5,822.65,642.6 103.2%   
Avg. wages/employee Rs Th1,050.51,032.4 101.8%   
Avg. net profit/employee Rs Th802.0320.9 249.9%   
INCOME DATA
Net Sales Rs m83,44476,728 108.8%  
Other income Rs m1,042571 182.7%   
Total revenues Rs m84,48677,299 109.3%   
Gross profit Rs m14,73419,831 74.3%  
Depreciation Rs m2,5286,177 40.9%   
Interest Rs m6515,038 12.9%   
Profit before tax Rs m12,5989,187 137.1%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-3,570 0.0%   
Tax Rs m1,1051,254 88.1%   
Profit after tax Rs m11,4934,363 263.4%  
Gross profit margin %17.725.8 68.3%  
Effective tax rate %8.813.6 64.3%   
Net profit margin %13.85.7 242.2%  
BALANCE SHEET DATA
Current assets Rs m54,96050,375 109.1%   
Current liabilities Rs m32,43351,653 62.8%   
Net working cap to sales %27.0-1.7 -1,621.1%  
Current ratio x1.71.0 173.8%  
Inventory Days Days8092 86.4%  
Debtors Days Days7268 105.6%  
Net fixed assets Rs m32,71083,648 39.1%   
Share capital Rs m239846 28.3%   
"Free" reserves Rs m61,36846,397 132.3%   
Net worth Rs m61,60747,244 130.4%   
Long term debt Rs m1,59239,129 4.1%   
Total assets Rs m99,433141,209 70.4%  
Interest coverage x20.42.8 721.2%   
Debt to equity ratio x00.8 3.1%  
Sales to assets ratio x0.80.5 154.4%   
Return on assets %12.26.7 183.5%  
Return on equity %18.79.2 202.0%  
Return on capital %21.012.3 169.9%  
Exports to sales %19.10-   
Imports to sales %3.00-   
Exports (fob) Rs m15,917NA-   
Imports (cif) Rs m2,483NA-   
Fx inflow Rs m16,06122,103 72.7%   
Fx outflow Rs m2,4835,522 45.0%   
Net fx Rs m13,57816,581 81.9%   
CASH FLOW
From Operations Rs m5,85117,981 32.5%  
From Investments Rs m-7,414-2,413 307.3%  
From Financial Activity Rs m792-13,145 -6.0%  
Net Cashflow Rs m-7312,380 -30.7%  

Share Holding

Indian Promoters % 66.9 71.5 93.6%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 33.1 7.0 471.5%  
FIIs % 0.0 12.6 -  
ADR/GDR % 0.0 0.0 -  
Free float % 0.0 8.8 -  
Shareholders   68,381 26,511 257.9%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALKEM LABORATORIES With:   ASTRAZENECA PHARMA  PANACEA BIOTECH  WOCKHARDT  NOVARTIS  FRESENIUS KABI ONCO.  

Compare ALKEM LABORATORIES With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

4 Factors Behind the Sensex Rally, Maruti Suzuki February Sales, and Buzzing Stocks Today(Pre-Open)

Indian share markets witnessed positive trading activity throughout the day yesterday and ended on a strong note.

Related Views on News

TORRENT PHARMA Announces Quarterly Results (2QFY21); Net Profit Up 27.0% (Quarterly Result Update)

Oct 27, 2020 | Updated on Oct 27, 2020

For the quarter ended September 2020, TORRENT PHARMA has posted a net profit of Rs 3 bn (up 27.0% YoY). Sales on the other hand came in at Rs 20 bn (up 0.6% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

TORRENT PHARMA Announces Quarterly Results (1QFY21); Net Profit Up 48.6% (Quarterly Result Update)

Jul 31, 2020 | Updated on Jul 31, 2020

For the quarter ended June 2020, TORRENT PHARMA has posted a net profit of Rs 3 bn (up 48.6% YoY). Sales on the other hand came in at Rs 21 bn (up 1.7% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

TORRENT PHARMA Announces Quarterly Results (3QFY20); Net Profit Up 2.0% (Quarterly Result Update)

Jan 28, 2020 | Updated on Jan 28, 2020

For the quarter ended December 2019, TORRENT PHARMA has posted a net profit of Rs 3 bn (up 2.0% YoY). Sales on the other hand came in at Rs 20 bn (down 4.1% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

TORRENT PHARMA Announces Quarterly Results (2QFY20); Net Profit Up 36.3% (Quarterly Result Update)

Nov 1, 2019 | Updated on Nov 1, 2019

For the quarter ended September 2019, TORRENT PHARMA has posted a net profit of Rs 2 bn (up 36.3% YoY). Sales on the other hand came in at Rs 20 bn (up 5.9% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

TORRENT PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 32.5% (Quarterly Result Update)

Jul 25, 2019 | Updated on Jul 25, 2019

For the quarter ended June 2019, TORRENT PHARMA has posted a net profit of Rs 2 bn (up 32.5% YoY). Sales on the other hand came in at Rs 20 bn (up 8.0% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

More Views on News

Most Popular

It's the Beginning of a New Bull Phase in Smallcaps(Profit Hunter)

Feb 24, 2021

Last time the smallcap index crossed 19k a big correction followed. Here's what makes it different this time.

Make Rs 5,000 Per Day Trading the Market(Fast Profits Daily)

Feb 25, 2021

In this video, I'll show you how to get started on the path to daily trading profits.

I Believe the Investment of the Year Will Be...

Feb 19, 2021

In this episode, ace trader Brijesh Bhatia talks to us about the best investments of 2021, his profitable trading system, and much more.

The Hidden Tesla in My Great Indian Wealth Project(Profit Hunter)

Feb 23, 2021

An Indian company founded three decades ago in a garage caught my attention...

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

ALKEM LABORATORIES SHARE PRICE


Mar 1, 2021 (Close)

TRACK ALKEM LABORATORIES

  • Track your investment in ALKEM LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ALKEM LABORATORIES

ALKEM LABORATORIES 5-YR ANALYSIS

COMPARE ALKEM LABORATORIES WITH

MARKET STATS